Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Buy ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of ...

Deutsche Bank initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $31 price target Maximize Your Portfolio with Data Driven ...

Deutsche Bank (ETR:DBKGn) initiated coverage on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) with a Buy rating and set a price target of $31.00. The new assessment comes as Denali's shares are seen ...

Denali Therapeutics DNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 128.8% in the 4th quarter, according to the company in its most recent filing ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) – Equities research analysts at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Denali Therapeutics in a research note ...